Placebo News and Research

RSS

Serono completes enrollment in phase III trial of Serostim

Serono has announced that it has completed enrollment in its second multi-center, phase III trial of Serostim (somatropin [rDNA origin] for injection) in the treatment of HIV-Associated Adipose Redistribution Syndrome (HARS).

24 Jan 2005

Are NSAIDS enough for cancer pain?

Non-steroidal anti-inflammatory drugs (NSAIDs) are effective in managing cancer pain with few side effects, according to a new review of a number of studies.

24 Jan 2005

Penicillin V and erythromycin have no benefit for most adults with acute laryngitis

Two common antibiotics, Penicillin V and erythromycin, appear to have no benefit for most adults with acute laryngitis, says a research team led by Dr. Ludovic Reveiz of Bogota, Colombia.

24 Jan 2005

NIH begins Phase 1 clinical trial of HIV vaccine candidate

GenVec announced today that the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), has begun the second Phase 1 clinical trial in healthy adult volunteers of an HIV vaccine candidate jointly developed by the Dale and Betty Bumpers Vaccine Research Center (VRC), a part of NIAID, and GenVec.

19 Jan 2005

Beneficial effects of essential fatty acids in children with autism and Asperger's syndrome

Nordic Naturals, a supplier of fish oil and essential fatty acid nutritional supplements, announced today the results of a successful pilot trial that showed beneficial effects of essential fatty acids (EFAs) on language and learning skills in children with autism and Asperger's syndrome.

19 Jan 2005

Physicians should avoid prescribing Bextra altogether

Physicians should avoid prescribing Bextra altogether, or use it only as a drug of last resort, says a researcher from Wake Forest University Baptist Medical Center and colleagues in an editorial published on-line Jan. 17 in Circulation, a publication of the American Heart Association.

19 Jan 2005

Estrogen therapy may increase risk for gallbladder disease

Dominic J. Cirillo, B.S., of the University of Iowa, Iowa City, and colleagues examined data from the Women’s Health Initiative (WHI), which were two randomized, double-blind, placebo-controlled trials conducted at 40 U.S. clinical centers.

19 Jan 2005

Animal study on vascular effects of COX-2 inhibition

In an article by Egan et al, titled, "Cyclooxygenases, Thromboxane, and Atherosclerosis," published in the Jan 17 issue of Circulation: Journal of the American Heart Association researchers examined some of the molecular mechanisms of drugs affecting prostaglandin and thromboxane production.

17 Jan 2005

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.

17 Jan 2005

Exciting research into the use of aspirin for reducing heart attacks, strokes and dementia

A consortium of researchers led by Monash University will receive more than $3.5 million in Australian Government funding for research into the use of aspirin for reducing heart attacks, strokes and dementia in older Australians.

17 Jan 2005

More data needed on what's effective for hot flashes

A University of Michigan expert on menopause says a new study that indicates placebos work as well as antidepressant drugs to help hot flashes shows how much more research is needed about what gives patients relief.

17 Jan 2005

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Myriad Genetics announced today that it has initiated enrollment in a Phase 3 human clinical trial of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's disease.

12 Jan 2005

Amarin announces positive results from studies using Miraxion to treat unresponsive depression

Amarin Corporation today announced positive data analysis from two exploratory phase IIa clinical studies using Miraxion (formerly referred to as LAX-101c) to treat depression.

12 Jan 2005

Campral, first new treatment for alcoholism in ten years

Forest Laboratories announced that Campral (acamprosate calcium) Delayed- Release Tablets are now available to physicians, patients and pharmacies nationwide.

12 Jan 2005

Modafinil may be a possible medicinal treatment for cocaine dependence

Cocaine dependence is a major public health problem affecting thousands of people around the globe. Despite years of active research there are still no approved medications for the treatment of this life-shattering addiction.

10 Jan 2005

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

InterMune, Inc. today announced that CHEST, the journal of the American College of Chest Physicians, published an important analysis of variables that measure clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF), a deadly and debilitating lung disease.

10 Jan 2005

Trial of naproxen and celecoxib suspended

Use of study drugs in a large, federally funded Alzheimer prevention trial has been suspended following a decision by the study's leadership on Dec. 17, 2004.

9 Jan 2005

Promising new evidence for the optimal use of biologic therapies for rheumatoid arthritis

A major cause of pain and disability, rheumatoid arthritis (RA) is also potentially the most treatable form of chronic arthritis. Researchers, doctors, and patients agree that a group of drugs called disease-modifying antirheumatic drugs (DMARDs) can effectively reduce joint pain and stiffness.

7 Jan 2005

European approval of Cymbalta/Xeristar for treatment of major depressive episodes

Eli Lilly and Company and Boehringer Ingelheim announced today that Cymbalta/Xeristar (duloxetine hydrochloride)(+) has been granted marketing authorization by the European Commission for the treatment of major depressive episodes.

5 Jan 2005

Stem cells from umbilical cord blood effectively treated heart attacks

When injected into rats' hearts soon after a heart attack, stem cells taken from human umbilical cord blood (HUCB) greatly reduced the size of heart damage and restored pumping function to near normal. This improvement occurred without the need for drugs to prevent the rats' immune system from rejecting the human cells.

5 Jan 2005

Placebo News and Research

Serono completes enrollment in phase III trial of Serostim

Are NSAIDS enough for cancer pain?

Penicillin V and erythromycin have no benefit for most adults with acute laryngitis

NIH begins Phase 1 clinical trial of HIV vaccine candidate

Beneficial effects of essential fatty acids in children with autism and Asperger's syndrome

Physicians should avoid prescribing Bextra altogether

Estrogen therapy may increase risk for gallbladder disease

Animal study on vascular effects of COX-2 inhibition

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

Exciting research into the use of aspirin for reducing heart attacks, strokes and dementia

More data needed on what's effective for hot flashes

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Amarin announces positive results from studies using Miraxion to treat unresponsive depression

Campral, first new treatment for alcoholism in ten years

Modafinil may be a possible medicinal treatment for cocaine dependence

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

Trial of naproxen and celecoxib suspended

Promising new evidence for the optimal use of biologic therapies for rheumatoid arthritis

European approval of Cymbalta/Xeristar for treatment of major depressive episodes

Stem cells from umbilical cord blood effectively treated heart attacks

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News